SCIENTIFIC AGENDA

Oral Presentations

---

NSCLC advanced disease I
Chairs: Chandra Belani, MD and David Gandara, MD
Discussants: Lawrence Einhorn, MD and David Gandara, MD

A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin^®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
Ulrich Gatzemeier, MD

Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599
Alan B. Sandler, MD

A multicenter phase IIB randomized study of the liposomal MUC1 vaccine L-BLP25 for immunotherapy of advanced non-small cell lung cancer (NSCLC)
Charles Butts, MD

NSCLC advanced disease I
Discussant: David R. Gandara, MD

Phase III trial of the protein kinase C б (PKCб) antisense oligonucleotide Aprinocarsen plus Gemcitabine/Cisplatin versus Gemcitabine/Cisplatin alone in advanced stage non-small cell lung cancer (NSCLC): Updated results of a randomized phase III trial
David R. Gandara, MD

A randomized phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
George Blumenschien, MD

Phase 2 study of bortezomib ± docetaxel in advanced non-small cell lung cancer (NSCLC)
Michael P. Fanucchi

Combining Novel Agents with Standard Chemotherapy
Discussant: Lawrence H. Einhorn, MD

---

NSCLC advanced disease III
Chairs: Ulrich Gatzemeier, MD and Vassilis Georgoulias
Discussants: Joseph Aisner, MD

Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable Non-small cell lung cancer (NSCLC)
Paris A. Kosmidis, MD

A phase III trial of docetaxel/ carboplatin versus mitomycin C/ ifosfamide/ cisplatin (MIC) or mitomycin C/ vinblastine/ cisplatin (MVP) in patients with advanced non-small cell lung cancer - A randomised multicentre trial of the British thoracic oncology group (BTOG1)
Paul Lorigan

Survival equivalence of non-platinum-based and platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): The results of a multicenter internet-based Phase III randomized study (D0112)
James Rigas, MD

Discussant: Joseph Aisner, MD

A randomized phase III trial of six versus four cycles of chemotherapy: Optimal duration of chemotherapy in advanced non-small-cell lung cancer: Korea cancer study group experience
Joon Oh Park, MD, PhD

Phase III Study in patients with Stage IV non small-cell lung cancer (NSCLC) treated with two cycles of Cisplatin/Gemcitabine followed by a randomization to three additional cycles of the same combination or Gemcitabine alone
Silvia Novello, MD

NSCLC advanced disease III (Discussion 2)
Discussant: Joseph Aisner, MD

---

Combined modality therapy involving definitive chemoradiation
Chairs: Nevin Murray and Hideo Kunitoh
Discussant: Andrew Turrisi and Mark A. Socinski, MD

(A randomized phase II trial of pre-operative docetaxel and cisplatin (DP) or docetaxel alone (D) in clinical (c-) stage IB/II nonsmall cell lung cancer (NSCLC): initial report of Japan Clinical Oncology Group trial (JCOG 0204)
Hirohito Tada, MD

Overall treatment time during concurrent chemoradiotherapy and outcomes: An RTOG secondary analysis
Mitchell Machtay, MD

Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): A Cancer and Leukemia Group B (CALGB) randomized phase II trial
Mark A. Socinski, MD

Impact of metronomic chemotherapy schedule on circulating VEGF and bFGF during concurrent thoracic radiotherapy
Yuhchau Chen, PhD, MD

What is the meaning of local-regional control after chemoradiation for locally advanced NSCLC? An RTOG analysis (abs. 1072)
Mitchell Machtay, MD

Combined modality therapy involving definitive chemoradiation
Discussant: Mark A. Socinski, MD